ReviewAmerican journal of surgery2012
Positron emission tomography in hepatobiliary and pancreatic malignancies: a review.
Review in American journal of surgery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 38 citations in OpenAlex.
- [Molecular imaging and biology · 2017Trial
- The effects of systemic inflammatory response on prognosis of pancreatic ductal adenocarcinoma.Annals of hepato-biliary-pancreatic surgery · 2019Article
- Article
- CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody.Theranostics · 2016Article
- Hepatolithiasis and intrahepatic cholangiocarcinoma: A review.World journal of gastroenterology · 2015Review
- Fluorine-18 Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma: Correlation with Glucose Transporters and p53 Expression.Journal of clinical and experimental hepatology · 2015Article
- Article
- Chronic Liver Disease and the Detection of Hepatocellular Carcinoma by [(18)F]fluorocholine PET/CT.Diagnostics (Basel, Switzerland) · 2015Article
- Cholangiocarcinoma.Lancet (London, England) · 2014Review
- Hepatic adenoma mimicking a metastatic lesion on computed tomography-positron emission tomography scan.World journal of gastroenterology · 2013Article
- Classification, diagnosis, and management of cholangiocarcinoma.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2013Review
- Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma.Journal of medicine and lifeReview
- Imaging Hepatocellular Carcinoma WithMolecular imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe prognosis for hepatobiliary and pancreatic malignancies is dismal. Surgery remains the primary curative option, but unresectable disease is often discovered during operative exploration. Positron emission tomography (PET) provides unique biological information different from current imaging modalities. The role of PET in detecting hepatobiliary and pancreatic malignancies has not yet been established. The purpose of this article was to review the literature on the use of PET in hepatobiliary and pancreatic malignancies. DATA SOURCES: We performed an extensive search on PubMed using PET and hepatocellular, pancreatic, gallbladder, and cholangiocarcinoma as keywords, excluding articles not written in English or on nonhuman subjects, case reports, and series with <5 patients.
conclusionsAlthough PET has shown usefulness in the diagnosis of certain cancers, current literature cautions against the use of PET for determining malignant potential of primary liver and pancreatic lesions. Literature on PET more strongly supports clinical roles for restaging of hepatobiliary and pancreatic malignancies, and for identifying metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.